SAN DIEGO, Feb. 10, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of transrenal molecular diagnostics, has announced that Stephen Zaniboni has been named Chief Financial Officer.
Mr. Zaniboni's experience includes raising more than $500 million through venture financing and IPO proceeds. Mr. Zaniboni previously served as Chief Financial Officer of healthcare software solutions company Awarepoint and XIFIN Inc., a provider of revenue cycle management for diagnostic service providers. Mr. Zaniboni has also served as Chief Financial Officer of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Mr. Zaniboni played an important role in the sale of AviaraDx to bioMerieux, which continues to operate the company under the name bioTheranostics. Before AviaraDx, Mr. Zaniboni served as CFO of Arcturus Bioscience Inc., where he played an important role in the sale of Arcturus' life science business assets to Molecular Devices Inc. Prior to Arcturus, from 1997 to 2005; Mr. Zaniboni served as Chief Financial Officer of Sequenom where he lead the efforts behind a very successful IPO. Mr. Zaniboni is co-founder of Sorrento Therapeutics, Inc. and served as a member of its board of directors until 2011. He was a practicing CPA with Arthur Andersen and holds a B.S. in accounting from Boston University and an M.B.A. from Boston College.
"I am pleased that Steve joins our team to lead the transition of Trovagene from a research stage organization to a commercial enterprise," states Antonius Schuh, Ph.D., Trovagene's Chief Executive Officer. "This transition requires an experienced Chief Financial Officer with a successful track record of raising capital, building organizations and creating value for shareholders. I look forward to working with him again."
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is developing its patente
|SOURCE Trovagene, Inc.|
Copyright©2010 PR Newswire.
All rights reserved